GiveTime Is All Set To Release Their Pre-Sale For Tokens
GiveTime.io has launched their new project wherein they will be releasing their tokens.
The team has plans of raising an amount in excess of $1,000,000 during the token sale phase itself. The investments that will pour in will be used to follow the roadmap that has already been sketched.
The project aims at improving the relationship between the healthcare professionals, the scientists and even the government so that everyone can benefit from it. They have a lot of long-term goals in place as they want to improve the speed and accuracy of diagnosis, increase the medical capacity and the abilities of the medical professionals. At the same time, focus is also there to increase the life expectancy by at least ten years.
This project is going to be launched on the Binance smart chain and the pre-sale price of the GTM is going to be fixed at $0.008. The DeFI price is going to be at $0.01.
As per reports, the pre-sale is all set to be scheduled for January 3, 2022 and last until January 10, 2022. There are future plans of tier 1 crypto exchanges that may take place.
Those who would like to know more about what the company has to offer and even those who would like to participate in the token sale should make it a point to visit https://givetime.io or send an email to info@givetime.io.
About GiveTime
GiveTime is going to launch one of the new projects that will deal with healthcare. The focus is on improving the life expectancy of people and will bring together government, scientists, and healthcare professionals. For updated follow them on Telegram @givetimeio or Twitter @givetimeio
Alexander Movchan
GiveTime
info@givetime.io
Visit us on social media:
Twitter
Other
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
